Motomi Konishi
Overview
Explore the profile of Motomi Konishi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
92
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hatakawa Y, Tanaka A, Furubayashi T, Katsumi H, Nakamura R, Konishi M, et al.
Eur J Pharm Biopharm
. 2025 Feb;
208:114661.
PMID: 39914573
JAL-TA9 (YKGSGFRMI), is a 9-residue catalytic peptide that cleaves amyloid β (Aβ) 42. Nasal administration was chosen to bypass the blood-brain barrier for efficient brain delivery of JAL-TA9 to treat...
2.
Nakamura R, Matsuda A, Higashi Y, Hayashi Y, Konishi M, Saito M, et al.
Biomolecules
. 2024 Oct;
14(10).
PMID: 39456166
There is a high demand for the development of drugs against Alzheimer's disease (AD), which is related to the misfolding and aggregation of Amyloid-β (Aβ), due to the increasing number...
3.
Hatakawa Y, Nakamura R, Akizawa T, Konishi M, Matsuda A, Oe T, et al.
Biomolecules
. 2024 May;
14(5).
PMID: 38785993
Despite the extensive research conducted on Alzheimer's disease (AD) over the years, no effective drug for AD treatment has been found. Therefore, the development of new drugs for the treatment...
4.
Nakamura R, Konishi M, Higashi Y, Saito M, Akizawa T
Alzheimers Res Ther
. 2023 Apr;
15(1):83.
PMID: 37076912
Background: The development of drugs for Alzheimer's disease (AD), which is related to the misfolding and aggregation of amyloid-β (Aβ), is high in demand due to the growing number of...
5.
Nakamura R, Akizawa T, Konishi M
Biomolecules
. 2022 Dec;
12(12).
PMID: 36551193
We recently discovered JAL-TA9 (YKGSGFRMI), a short hydrolytic peptide that we termed a Catalytide. The catalytic center of JAL-TA9 was modeled using MM2 and MMFF94 parameters and identified as GSGFR....
6.
Hatakawa Y, Tanaka A, Furubayashi T, Nakamura R, Konishi M, Akizawa T, et al.
Pharmaceutics
. 2021 Oct;
13(10).
PMID: 34683967
We have recently reported Catalytides (Catalytic peptides) JAL-TA9 (YKGSGFRMI) and ANA-TA9 (SKGQAYRMI), which are the first Catalytides found to cleave Aβ42. Although the Catalytides must be delivered to the brain...
7.
Hatakawa Y, Nakamura R, Konishi M, Sakane T, Tanaka A, Matsuda A, et al.
Alzheimers Dement (N Y)
. 2021 Apr;
7(1):e12146.
PMID: 33816760
Introduction: We recently discovered a short synthetic peptide derived from the ANA/BTG3 protein Box A region called ANA-TA9 (SKGQAYRMI), which possesses catalytic activity. Herein we demonstrated the proteolytic activity of...
8.
Hatakawa Y, Nakamura R, Konishi M, Sakane T, Saito M, Akizawa T
Heliyon
. 2019 Nov;
5(9):e02454.
PMID: 31687556
We have recently reported about shorter proteolytic peptides termed Catalytide as general name. JAL-TA9 (YKGSGFRMI), a fragment peptide derived from Box A region of Tob1 protein, is the first Catalytide...
9.
Sakaguchi Y, Nakamura R, Konishi M, Hatakawa Y, Toyoda H, Akizawa T
Biochem Biophys Res Commun
. 2019 May;
514(3):798-802.
PMID: 31079927
Prion diseases are neurodegenerative disorders caused by misfolding of the prion protein (PrP) from a normal cellular protein (PrP) to a protease-resistant isoform (PrP). However, the aggregation mechanism is not...
10.
Nakamura R, Konishi M, Taniguchi M, Hatakawa Y, Akizawa T
Peptides
. 2019 Apr;
116:71-77.
PMID: 30930080
We screened nearly 1000 synthetic peptides and found that JAL-AK22 (KYEGHWYPEKPYKGSGFRCIHI), which is derived from the BoxA domain in the Tob1 protein, activates both unfolded and folded proMMP-7. Interestingly, the...